Clinical trials in Hamburg – page 45

1 128 clinical trials in Hamburg, Germany across 19 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Hamburg at a glance

1 128

clinical trials

Research sites19

Quick filters

1 128 trials in Hamburg

Open in trial search

Non-small cell lung cancer

Not yet recruiting

Study of Izalontamab Brengitecan versus Platinum-based Chemotherapy for Patients with EGFR-mutated Non-small Cell Lung Cancer after EGFR Inhibitor Treatment

Registered drugNo placebo

Study of Izalontamab Brengitecan versus Platinum-based Chemotherapy for Patients with EGFR-mutated Non-small Cell Lung Cancer after EGFR Inhibitor Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Colorectal cancer metastatic

Not yet recruiting

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Myasthenia gravis

Not yet recruiting

Study of TOL2 safety and immune response in patients with generalized myasthenia gravis

Registered drug

Study of TOL2 safety and immune response in patients with generalized myasthenia gravis

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Glucose

Contact Research Centre

Type 2 diabetes mellitus

Not yet recruiting

Comparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before

Registered drugNo placebo

Comparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:INSULIN DEGLUDEC
Sponsor:Novo Nordisk A/S

Contact Research Centre

Neuronal ceroid lipofuscinosis

Not yet recruiting

First study of TTX-381 gene therapy safety in patients with eye problems caused by CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2)

InvestigationalNo placebo

First study of TTX-381 gene therapy safety in patients with eye problems caused by CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2)

InvestigationalNo placebo

Germany

Participants:0–17 years
Substances:TTX-381
Sponsor:Tern Therapeutics LLC

Contact Research Centre

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Glatiramer Acetate
Sponsor:Torl Biotherapeutics LLC

Contact Research Centre

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Carboplatin
Sponsor:GPOH gGmbH

Contact Research Centre

Neovascular age-related macular degeneration

Not yet recruiting

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Study on the Spread of LetibotulinumtoxinA Compared to OnabotulinumtoxinA and AbobotulinumtoxinA in Patients with Moderate to Severe Forehead Wrinkles

Not yet recruiting

Registered drugNo placebo

Study on the Spread of LetibotulinumtoxinA Compared to OnabotulinumtoxinA and AbobotulinumtoxinA in Patients with Moderate to Severe Forehead Wrinkles

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Botulinum Toxin Type A
Sponsor:Hamburg University

Contact Research Centre

Enterobacter infection

Not yet recruiting

Study on the Effectiveness of Intestifix, Colistin Sulfate, and Vancomycin for Patients with Infections from Multidrug-Resistant Enterobacteriaceae

Registered drugNo placebo

Study on the Effectiveness of Intestifix, Colistin Sulfate, and Vancomycin for Patients with Infections from Multidrug-Resistant Enterobacteriaceae

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Colistin Sulfate
Sponsor:Goethe University Frankfurt

Contact Research Centre

Colorectal cancer

Not yet recruiting

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Gastrooesophageal cancer+1

Not yet recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Hamburg

What the registry says about research in the country

01 Oncology Research

Current clinical trials focusing on innovative treatments for metastatic prostate cancer, colorectal cancer, and breast cancer. Studies are evaluating new therapeutic combinations and targeted approaches for improved patient outcomes.

Advanced cancer therapies
Immunotherapy combinations
Treatment resistance strategies

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting respiratory syncytial virus, cytomegalovirus, and meningococcal infections. Research focuses on both adult and pediatric populations.

Vaccine immunogenicity
Long-term protection
Novel vaccine platforms

03 Neurological Conditions

Groundbreaking research in treating acute cerebral ischemic stroke with innovative therapies. Studies are evaluating functional outcomes and safety profiles of new therapeutic agents.

Stroke treatment
Neuroprotective strategies
Recovery outcomes

04 Women's Health

Clinical investigations addressing vaginal atrophy and contraceptive technologies. Research includes novel delivery systems and hormone-based treatments for postmenopausal conditions.

Reproductive health
Hormone therapy
Novel delivery systems

Back to Germany All countries